Funding for this research was provided by:
Foundation for the National Institutes of Health (R01HD087292)
Text and Data Mining valid from 2019-07-26
Received: 22 January 2019
Accepted: 11 July 2019
First Online: 26 July 2019
Ethics approval and consent to participate
: Our study, which is the review of aggregate clinical data, was approved by Baylor College of Medicine Institutional Review Board with the waiver of informed consent granted. De-identified reporting of demographic and molecular data from this laboratory was approved by the Institutional Review Board at Baylor College of Medicine (H-42680 and H-41191). For clinical testing, exome tests involving minor or fetal sample required informed consent, which was obtained from parents. This research conformed with the principles of the Declaration of Helsinki.
: Not applicable.
: BCM and Miraca Holdings Inc. have formed a joint venture with shared ownership and governance of Baylor Genetics (BG), formerly the Baylor Miraca Genetics Laboratories (BMGL), which performs chromosomal microarray analysis and clinical exome sequencing. PW, LM, RX, WB, FX, CS, CE, PL, and PS are current employees of BCM and derive support through a professional service agreement with BG. TC, YF, EG, and FG are current employees of BG. The remaining authors declare that they have no competing interests.